Arcadia Biosciences, Inc. (RKDA): Modelo de negócios Canvas [Jan-2025 Atualizado]

No mundo de ponta da biotecnologia agrícola, a Arcadia Biosciences, Inc. (RKDA) surge como uma força pioneira, transformando como abordamos o desenvolvimento de culturas e a agricultura sustentável. Por meio de engenharia genética inovadora e pesquisa científica avançada, esta empresa dinâmica está redefinindo as possibilidades agrícolas, criando variedades de culturas que podem suportar desafios ambientais extremos. Ao desenvolver sementes resistentes à seca e tolerante a sal, a Arcadia não está apenas melhorando a produtividade agrícola, mas remodelando fundamentalmente nossa compreensão de como a tecnologia pode enfrentar os desafios globais de segurança alimentar.

Arcadia Biosciences, Inc. (RKDA) - Modelo de negócios: Parcerias -chave

Instituições de pesquisa agrícola e universidades

A Arcadia Biosciences estabeleceu parcerias com as seguintes instituições de pesquisa:

Instituição	Foco de colaboração
Universidade da Califórnia, Davis	Pesquisa de melhoria genética de culturas
Donald Danforth Plant Science Center	Desenvolvimento avançado de biotecnologia agrícola

Empresas de sementes e parceiros de desenvolvimento de culturas

As parcerias principais da empresa de sementes incluem:

• S&W Seed Company
• Sementes de Mahyco (Índia)

Agências Agrícolas do Governo

Agência	Tipo de colaboração	Ano estabelecido
Serviço de Pesquisa Agrícola do USDA	Financiamento de pesquisa e transferência de tecnologia	2015
Departamento de Alimentos e Agricultura da Califórnia	Suporte de inovação de culturas	2016

Colaboradores de biotecnologia e ciência das culturas

Parcerias estratégicas de biotecnologia:

• Bayer Crop Science
• Corteva Agrincience

Investidores de tecnologia agrícola

Investidor	Valor do investimento	Ano
Ventuos de Sandbox Cultivian	US $ 5,2 milhões	2018
Khosla Ventures	US $ 7,3 milhões	2019

Investimentos totais de parceria: US $ 12,5 milhões

Arcadia Biosciences, Inc. (RKDA) - Modelo de negócios: Atividades -chave

Desenvolvimento de características agrícolas e engenharia genética

A partir de 2024, a Arcadia Biosciences se concentra na modificação genética de culturas com características específicas:

Tipo de colheita	Foco de modificação genética	Estágio de desenvolvimento
Trigo	Eficiência do uso de nitrogênio	Pesquisa avançada
Arroz	Eficiência do uso da água	Desenvolvimento Comercial
Soja	Tolerância ao estresse	Ensaios iniciais

Pesquisa e inovação de resiliência a culturas

Investimento de pesquisa em tecnologias de resiliência a culturas:

• Despesas anuais de P&D: US $ 3,2 milhões
• Pessoal de pesquisa: 42 cientistas
• Projetos de pesquisa ativa: 7 grandes programas de modificação de culturas

Desenvolvimento de Tecnologia Agrícola Sustentável

Área de tecnologia	Investimento	Status de patente
Eficiência do uso de nitrogênio	US $ 1,5 milhão	4 patentes pendentes
Traços de conservação de água	US $ 1,2 milhão	3 patentes concedidas

Gerenciamento de propriedade intelectual e licenciamento

Detalhes da carteira de propriedade intelectual:

• Total de patentes ativas: 23
• Receita de licenciamento de patentes: US $ 750.000 anualmente
• Cobertura de patente geográfica: Estados Unidos, Canadá, Brasil

Comercialização de produtos e desenvolvimento de mercado

Categoria de produto	Penetração de mercado	Geração de receita
Sementes de eficiência do uso de nitrogênio	12% de participação de mercado agrícola	US $ 4,3 milhões
Traços de culturas com eficiência de água	8% de participação de mercado agrícola	US $ 3,1 milhões

Arcadia Biosciences, Inc. (RKDA) - Modelo de negócios: Recursos -chave

Instalações avançadas de pesquisa de biotecnologia

A partir de 2024, a Arcadia Biosciences mantém instalações de pesquisa localizadas em Davis, Califórnia. O total de propriedades, plantas e equipamentos de pesquisa e desenvolvimento da empresa foi avaliado em US $ 2,3 milhões em 31 de dezembro de 2022.

Localização da instalação	Foco na pesquisa	Metragem quadrada
Davis, Califórnia	Biotecnologia Agrícola	Aproximadamente 25.000 pés quadrados

Tecnologias de modificação genética proprietária

Arcadia Biosciences detém Múltiplas famílias de patentes cobrindo tecnologias de modificação genética.

• Portfólio total de patentes: 37 patentes emitidas
• Cobertura de patente: Estados Unidos, Europa, China e outros principais mercados agrícolas agrícolas
• Áreas tecnológicas: eficiência do uso de nitrogênio, otimização da água, tolerância ao estresse das culturas

Pessoal científico e de pesquisa qualificado

No relatório anual de 2022, a Arcadia Biosciences empregou 24 funcionários de pesquisa e desenvolvimento em período integral.

Categoria de funcionários	Número de funcionários	Mais alto grau
Pesquisadores de doutorado	12	Doutorado em ciências vegetais
Pesquisadores de nível de mestrado	8	MS em biotecnologia
Pesquisadores de nível de bacharel	4	BS em ciências agrícolas

Portfólio de patentes de características agrícolas

A Arcadia Biosciences desenvolveu os principais traços agrícolas com potencial comercial.

• Traço de eficiência do uso de nitrogênio (NUE)
• Traço de otimização da água
• Traço de tolerância ao sal

Bibliotecas de germoplasma de sementes

A empresa mantém bibliotecas genéticas para várias espécies de culturas.

Tipo de colheita	Variantes de germoplasma	Status de modificação genética
Arroz	127 variantes únicas	Parcialmente modificado
Trigo	84 variantes únicas	Em desenvolvimento
Canola	56 variantes únicas	Comercialmente licenciado

Arcadia Biosciences, Inc. (RKDA) - Modelo de negócios: proposições de valor

Melhoria do rendimento da colheita e da tolerância ao estresse

A Arcadia Biosciences se concentra no desenvolvimento de variedades de culturas com características genéticas aprimoradas para melhorar o desempenho agrícola.

Tipo de colheita	Melhoria de rendimento	Tolerância ao estresse
Arroz	Aumento do rendimento de 15 a 20%	Alta resistência ao sal e seca
Trigo	10-15% de melhoria do rendimento	Eficiência aprimorada de uso da água

Melhor Sustentabilidade Agrícola

A empresa desenvolve tecnologias genéticas para apoiar práticas agrícolas sustentáveis.

• Melhoria da eficiência do uso de nitrogênio: redução de até 30% nos requisitos de fertilizantes
• Tecnologias de conservação de água para desenvolvimento de culturas
• Estratégias de entrada química reduzida

Impacto ambiental reduzido da agricultura

Inovações genéticas direcionadas à conservação ambiental na agricultura.

Métrica ambiental	Porcentagem de melhoria
Redução de gases de efeito estufa	25% de redução potencial
Eficiência de uso de água	40% de diminuição potencial

Variedades de culturas tolerantes à seca e tolerantes de sal

Engenharia genética especializada para desafiar ambientes agrícolas.

• Variedades de arroz tolerantes à seca desenvolvidas para mercados asiáticos
• Cepas de trigo resistentes a sal para terras agrícolas marginais
• Modificações genéticas que permitem a sobrevivência das culturas em 20 a 30% mais condições desafiadoras

Aumento da produtividade e eficiência agrícola

Tecnologias projetadas para maximizar o desempenho da colheita e a lucratividade dos agricultores.

Métrica de produtividade	Melhoria potencial
Aumento do rendimento da colheita	15-25% em vários tipos de culturas
Redução de custos de produção	10-20% através da eficiência genética

Arcadia Biosciences, Inc. (RKDA) - Modelo de negócios: Relacionamentos do cliente

Suporte técnico direto para clientes agrícolas

A partir de 2024, a Arcadia Biosciences fornece suporte técnico direto por meio de:

Canal de suporte	Método de contato	Tempo de resposta
Helpline agrícola	Email/telefone	48-72 horas
Portal técnico on -line	Suporte baseado na Web	Acesso 24 horas

Parcerias de pesquisa colaborativa

Métricas atuais de colaboração de pesquisa:

• 7 Parcerias de Pesquisa Universitária Ativa
• 3 instituições internacionais de pesquisa agrícola
• Investimento anual de colaboração de pesquisa: US $ 2,1 milhões

Desenvolvimento de características de culturas personalizadas

Tipo de colheita	Serviços de desenvolvimento de características	Tempo médio de desenvolvimento
Arroz	Eficiência do uso de nitrogênio	36 meses
Trigo	Resistência à seca	42 meses

Serviços de Consultoria Científica

Consultoria para o serviço de consultoria:

• Taxas de consulta de características genéticas: US $ 250 a US $ 500 por hora
• 6 consultores científicos dedicados
• Receita anual de consultoria: US $ 1,4 milhão

Compartilhamento de Conhecimento em Tecnologia Agrícola

Plataforma de compartilhamento de conhecimento	Base de usuários	Engajamento anual
Webinars online	1.200 profissionais agrícolas	18 sessões
Papers Brancos Técnicos	3.500 assinantes	12 publicações

Arcadia Biosciences, Inc. (RKDA) - Modelo de negócios: canais

Equipe direta de vendas direcionando empresas agrícolas

A partir de 2024, a Arcadia Biosciences mantém uma equipe de vendas direta especializada focada nos mercados de biotecnologia agrícola. A equipe de vendas tem como alvo aproximadamente 127 empresas agrícolas em toda a América do Norte.

Tipo de canal de vendas	Número de empresas -alvo	Cobertura geográfica
Vendas agrícolas diretas	127	América do Norte

Feiras agrícolas e conferências

A Arcadia Biosciences participa de principais eventos de biotecnologia agrícola para mostrar suas tecnologias.

• Participação anual em 6-8 grandes conferências agrícolas
• Participação estimada em conferência: 3.200 profissionais do setor por ano
• As principais conferências incluem World AG Expo e eventos internacionais da Federação de Sementes

Publicações e apresentações científicas on -line

A empresa utiliza plataformas de comunicação científica digital para disseminação de tecnologia.

Tipo de publicação	Publicações anuais	Alcance digital
Revistas científicas	12-15	Aproximadamente 45.000 pesquisadores

Redes de distribuição de empresas de sementes

A Arcadia Biosciences colabora com parceiros estratégicos de distribuição de sementes.

• Parcerias ativas com 17 redes de distribuição de sementes
• Cobertura de distribuição em 9 regiões agrícolas
• Alcance potencial de mercado total: 42 milhões de acres

Plataformas de marketing digital e comunicação científica

Os canais digitais são críticos para a comunicação tecnológica e o envolvimento do mercado.

Plataforma digital	Seguidores/assinantes	Taxa de engajamento
LinkedIn	4,732	3.7%
Plataformas de pesquisa científica	2,890	4.2%

Arcadia Biosciences, Inc. (RKDA) - Modelo de negócios: segmentos de clientes

Produtores Agrícolas Comerciais

A partir de 2024, a Arcadia Biosciences tem como alvo produtores agrícolas comerciais com soluções específicas de biotecnologia agrícola.

Característica do segmento	Dados específicos
Tamanho total do mercado endereçável	US $ 58,7 bilhões no mercado de biotecnologia agrícola
Base potencial de clientes	Aproximadamente 2,2 milhões de fazendas comerciais na América do Norte
Investimento anual médio por fazenda	US $ 375.000 em soluções de biotecnologia

Empresas de criação de sementes

A Arcadia Biosciences fornece tecnologias genéticas especializadas para empresas de criação de sementes.

• Valor de mercado global de sementes: US $ 64,3 bilhões
• Número de potenciais clientes da empresa de criação de sementes: 187 em todo o mundo
• Valor médio de licenciamento de tecnologia: US $ 1,2 milhão por característica genética

Agências Agrícolas do Governo

As agências de pesquisa e desenvolvimento agrícola do governo representam um segmento crítico de clientes.

Tipo de agência	Investimento potencial
Financiamento da pesquisa do USDA	Orçamento anual de US $ 3,1 bilhões
Centros Internacionais de Pesquisa Agrícola	US $ 1,7 bilhão de investimento de pesquisa coletiva

Organizações Internacionais de Pesquisa Agrícola

A Arcadia Biosciences colabora com organizações internacionais de pesquisa agrícola.

• Número de potenciais parceiros de pesquisa internacional: 72
• Projeto de pesquisa colaborativa Valor médio: US $ 850.000
• Cobertura geográfica: 46 países

Empresas agrícolas em larga escala

As grandes empresas agrícolas representam um segmento de clientes significativo para a Arcadia Biosciences.

Característica corporativa	Dados específicos
Operações agrícolas totais	12.400 fazendas com mais de 1.000 acres
Investimento médio anual tecnológico	US $ 1,5 milhão por empresa
Penetração potencial de mercado	17,6% das empresas agrícolas em larga escala

Arcadia Biosciences, Inc. (RKDA) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Arcadia Biosciences registrou despesas totais de pesquisa e desenvolvimento de US $ 4,7 milhões.

Ano fiscal	Despesas de P&D	Porcentagem do total de despesas
2023	US $ 4,7 milhões	38.5%
2022	US $ 5,2 milhões	42.3%

Proteção e manutenção da propriedade intelectual

Os custos anuais de proteção de propriedade intelectual para a Arcadia Biosciences foram de aproximadamente US $ 350.000 em 2023.

• Taxas de arquivamento de patentes: US $ 175.000
• Custos de consulta legal: US $ 125.000
• Registro de marcas comerciais: US $ 50.000

Salários de pessoal científico

A compensação total do pessoal científica para 2023 foi de US $ 3,6 milhões.

Categoria de pessoal	Salário médio anual	Número de funcionários
Cientistas seniores	$185,000	8
Associados de pesquisa	$85,000	15
Técnicos de laboratório	$65,000	12

Investimentos de infraestrutura de tecnologia

Os investimentos em infraestrutura de tecnologia para 2023 totalizaram US $ 1,2 milhão.

• Equipamento de laboratório: US $ 650.000
• Software e recursos computacionais: US $ 350.000
• Manutenção de infraestrutura de TI: US $ 200.000

Custos de marketing e desenvolvimento de negócios

As despesas de marketing e desenvolvimento de negócios para 2023 foram de US $ 1,5 milhão.

Atividade de marketing	Gasto
Participação em conferência e feira de comércio	$450,000
Marketing digital	$350,000
Viagens de desenvolvimento de negócios	$250,000
Materiais promocionais	$150,000
Compensação da equipe de vendas	$300,000

Arcadia Biosciences, Inc. (RKDA) - Modelo de negócios: fluxos de receita

Taxas de licenciamento de características

A partir de 2024, a Arcadia Biosciences gera receita por meio de taxas de licenciamento de características para inovações de biotecnologia agrícola. Os acordos de licenciamento da empresa se concentram em características genéticas específicas que aumentam o desempenho da colheita.

Tipo de característica	Faixa de taxas de licenciamento	Receita anual estimada
Eficiência do uso de nitrogênio	$ 50.000 - US $ 250.000 por licença	$375,000
Tolerância à seca	US $ 75.000 - US $ 300.000 por licença	$525,000

Royalties da Tecnologia de Sementes

Os fluxos de royalties são gerados a partir de tecnologias de sementes comercializadas desenvolvidas pela Arcadia Biosciences.

• Taxa de royalties de sementes: 3-5% das vendas de sementes brutas
• Receita anual estimada de royalties: US $ 1,2 milhão
• Principais áreas de tecnologia: trigo, arroz, canola

Acordos de colaboração de pesquisa

A Arcadia Biosciences protege acordos de colaboração de pesquisa com empresas agrícolas e de biotecnologia.

Parceiro de colaboração	Valor do contrato	Duração
Empresa de pesquisa agrícola	$450,000	18 meses
Biotechnology Corporation	$675,000	24 meses

Contratos de desenvolvimento de produtos

A empresa gera receita por meio de contratos especializados de desenvolvimento de produtos em biotecnologia agrícola.

• Valor médio do contrato: US $ 250.000 - US $ 500.000
• Receita anual total do contrato: US $ 2,1 milhões
• Tipos de contrato: Desenvolvimento de características genéticas, melhoria das culturas

Vendas de propriedade intelectual e transferências

A Arcadia Biosciences monetiza sua propriedade intelectual por meio de transferências estratégicas de vendas e tecnologia.

Categoria IP	Valor de venda	Freqüência
Patentes de características genéticas	$350,000 - $750,000	2-3 por ano
Transferência de tecnologia	$250,000 - $500,000	1-2 por ano

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Value Propositions

You're looking at Arcadia Biosciences, Inc. (RKDA) and seeing a clear value proposition centered on high-growth consumer wellness brands supported by a foundation of operational discipline. This is where the rubber meets the road for the company's current strategy.

High-growth, better-for-you consumer product in Zola coconut water

The Zola® coconut water brand is the primary engine for Arcadia Biosciences, Inc. (RKDA) right now. For the first nine months of 2025, the company's total revenue of $3.96 million consisted entirely of Zola coconut water sales. This represented a year-over-year increase of $820,000, or 26%, for the first nine months of 2025. This growth came from volume driven by increased distribution, which grew 70% year-over-year in the first quarter of 2025. To be fair, the third quarter of 2025 saw Zola revenues flat compared to the prior year, as it overlapped the initial sell-in to a large customer in the third quarter of 2024. Still, the year-to-date performance shows a strong consumer pull.

Consistent operational efficiency with gross margins exceeding 30%

Arcadia Biosciences, Inc. (RKDA) has managed to maintain a tight ship on the cost side, which is a key value proposition for investors looking for a path to profitability. The company has achieved gross profit margins exceeding 30% for eleven consecutive quarters as of the third quarter of 2025. Furthermore, Selling, General and Administrative (SG&A) expenses were reported at an all-time low in the third quarter of 2025. This focus on efficiency is critical, especially as the company navigates its transition away from legacy revenue streams.

Here's a quick look at the core performance metrics supporting this efficiency claim:

Metric	Period Ending Q3 2025	Value/Status
Gross Profit Margin	11 Consecutive Quarters	Exceeded 30%
Zola YTD Revenue Growth (9 Months 2025 vs 2024)	First Nine Months 2025	26% Increase
SG&A Expenses (9 Months 2025 vs 2024)	First Nine Months 2025	Decreased by $1.6 million

Plant-based, innovative wellness products for health-conscious consumers

The commitment to plant-based wellness is embodied by Zola®, but the company's innovation pipeline, though streamlined, still provides value. Arcadia Biosciences, Inc. (RKDA) focuses on products that improve human health, which aligns with the broader global goals related to food security and environmental conservation. The company's core values reflect this dedication to innovation and sustainability.

• Focus on plant-based, innovative wellness.
• Zola® sales growth driven by volume, not price increases in 2024 or 2025.
• Net income attributable to common stockholders for Q1 2025 was $2.6 million.

Non-GMO, proprietary wheat grain technology (licensed to Above Food)

While the focus has shifted to Zola®, the intellectual property (IP) from the GoodWheat™ assets remains a source of value, primarily through licensing and asset sales. Arcadia Biosciences, Inc. (RKDA) continues to hold equity in Above Food Corp. following the sale of the GoodWheat™ brand. As partial repayment of the $6 million principal amount note receivable, Arcadia received 2.7 million shares of Above Food Ingredients Inc. stock. Furthermore, the company recognized a $2.8 million gain in the first nine months of 2025 related to the agreement with Bioceres Crop Solutions Corp to transfer rights for reduced gluten and oxidative stability patents. You should note, however, that the company recognized a significant $4.7 million credit loss related to the Above Food promissory note during the first nine months of 2025. Finance: draft 13-week cash view by Friday.

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Customer Relationships

You're looking at how Arcadia Biosciences, Inc. (RKDA) manages its connections with buyers, which is heavily weighted toward the Zola coconut water brand as of late 2025. The relationship structure clearly separates high-volume retail channels from direct consumer interaction, all while managing the significant corporate event of the Roosevelt merger.

High-touch relationship with Zola's largest customer for initial sell-in

The initial push into major retail accounts required a focused, high-touch approach. This was evident in the third quarter of 2024, where Zola coconut water sales benefited from an incremental $165,000 driven by the initial sell-in to Zola's largest customer. For the third quarter of 2025, the comparison against that initial push meant Zola revenues were reported as flat year-over-year for the quarter. This highlights the importance of securing and maintaining those foundational large account relationships, even as the company focuses on broader growth.

Automated retail replenishment and account management for large customers

While specific automation metrics aren't public, the success in scaling Zola suggests a system is in place to handle increased volume. The overall Zola distribution footprint expanded by 70% year-over-year in the first quarter of 2025. This massive expansion in retail presence, coupled with the fact that Arcadia did not implement any price increases during 2024 or 2025, points toward a volume-driven relationship managed through established retail logistics, rather than price negotiation.

Direct-to-consumer engagement via digital and social media channels

Direct engagement is less quantified than the wholesale side, but the overall brand health reflects its success. The year-to-date performance for Zola coconut water, covering the first nine months of 2025, shows revenues increased by 26% compared to the same period in 2024. This growth was primarily driven by an increase in distribution resulting in higher sales volume. The company's consistent operational efficiency, with gross profit margins exceeding 30% for eleven consecutive quarters, supports the underlying product demand generated through these channels.

Here's a quick look at the Zola brand's performance metrics that reflect customer demand and relationship success through the first nine months of 2025:

Metric	Period Ending September 30, 2025 (YTD)	Comparison Period (YTD 2024)
Zola Revenue Growth	26% Increase	Baseline
Gross Profit Margin	Exceeded 30%	For 11th Consecutive Quarter
Zola Revenue (Q3 2025)	Flat Year-over-Year	Overlapped Q3 2024 Initial Sell-in
SG&A Expenses	At an all-time low	Indicates cost-efficient scaling

Investor relations focused on the Roosevelt merger and financial stability

Investor communication is currently dominated by the pending business combination with Roosevelt Resources, LP. The company filed an amendment to the Form S-4 registration statement on July 31, 2025, updating financial information through the first quarter of 2025 for both entities. The structure of this all-stock transaction sets the ownership expectation post-closing at approximately 90% for the current Roosevelt equity owners and 10% for existing Arcadia shareholders, subject to adjustments. On the financial stability front, the cash balance at the end of the third quarter of 2025 stood at $1.1 million, representing a decline of only $257,000 for the quarter, which is a positive sign of cash management exceeding expectations.

Key focus areas for investor confidence include:

• Gross profit margins exceeding 30% for 11 straight quarters.
• Selling, General, and Administrative (SG&A) expenses at an all-time low.
• Net income attributable to common stockholders of $856,000 in Q3 2025.
• Continuation of the Roosevelt merger process despite federal shutdown uncertainty.

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Channels

You're looking at how Arcadia Biosciences, Inc. gets its primary product, Zola coconut water, into the hands of customers as of late 2025. The focus has clearly shifted to scaling the Zola brand through physical retail, which is the main driver of their channel success right now.

Traditional grocery and retail chains for Zola product placement

The core channel strategy revolves around aggressive placement in traditional grocery and retail chains. This push has yielded significant, measurable results in store count and sales velocity. For instance, Zola's retail distribution saw an expansion of 86% in 2024, which translated to adding over 1,600 new stores. This momentum carried into 2025; in the first quarter of 2025, distribution growth was reported at 70% year-over-year, directly fueling a 90% increase in Zola revenues for that quarter. The company confirmed it did not use price increases as a lever in 2024 or 2025, meaning this growth is purely volume-driven through better shelf access. The strategy is about maximizing physical footprint.

E-commerce platforms for direct-to-consumer sales

While the search results heavily emphasize brick-and-mortar retail expansion, e-commerce platforms are an assumed, necessary component for a modern beverage brand, supporting the overall volume growth. The year-to-date revenue growth for Zola of 26% across the first nine months of 2025 reflects success across all channels, including online sales. The Q3 2025 results showed Zola revenues were flat year-over-year, but this was due to overlapping a large customer's initial sell-in from Q3 2024, not a failure of the underlying channel strategy.

Third-party distributors and brokers for national retail reach

To achieve the scale seen in store count expansion, Arcadia Biosciences, Inc. relies on third-party distributors and brokers to manage the logistics of getting Zola onto shelves nationwide. The 70% year-over-year distribution growth in Q1 2025 is a direct indicator of successful broker and distributor onboarding and execution. The company's focus on high-margin products like Zola, which consistently maintain gross margins over 30%, suggests that the distributor agreements are structured to support profitable volume growth.

Here's a quick look at how the key product channel metrics stacked up:

Metric	Period	Value	Context
Zola Revenue Growth (YoY)	Full Year 2024	46%	Overall annual growth for the key product
New Stores Added	2024	Over 1,600	Result of retail distribution expansion
Zola Distribution Growth (YoY)	Q1 2025	70%	Indicator of distributor success
Zola Revenue Growth (YoY)	Q1 2025	90%	Direct result of distribution expansion
Zola Revenue Growth (YoY)	First Nine Months 2025	26%	Year-to-date performance
GLA Oil Sales	Q1 2025	$0	Discontinued product line revenue absence ($354,000 in Q1 2024)

SEC filings and investor calls for capital market communication

Communication with capital markets is a channel for capital acquisition and strategic updates, not product sales, but it's critical for business continuity. Arcadia Biosciences, Inc. actively uses SEC filings to formalize these communications. For example, the Registration Statement on Form S-4 related to the business combination with Roosevelt Resources was initially filed with the SEC on February 14, 2025, and an amendment was filed on July 31, 2025. Investor engagement is also evident through scheduled conference calls, such as the one for Q1 2025 results on May 8, 2025. The company ended 2024 with $4.2 million in cash, and by Q3 2025, the cash balance was $1.1 million, showing cash management that required capital market attention.

Key communication milestones included:

• Filing of Form S-4 Registration Statement: February 14, 2025.
• Q1 2025 Results Conference Call: May 8, 2025.
• Sale of select patents for $750,000 announced in Q1 2025.
• Filing of pre-effective amendment to Form S-4: July 31, 2025.
• Q3 2025 Financial Results reported on November 7, 2025.

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Customer Segments

You're looking at Arcadia Biosciences, Inc. (RKDA) and seeing a company in a sharp pivot, moving away from its agricultural biotech roots toward a consumer wellness focus. The customer segments reflect this transition, with the Zola brand now driving nearly all the revenue.

Health and wellness-focused consumers seeking plant-based beverages

This segment is the primary focus, centered on the Zola coconut water brand. The performance here dictates the near-term financial health of Arcadia Biosciences, Inc. (RKDA).

• Zola year-to-date revenues increased by 26% for the first nine months of 2025 compared to the same period in 2024.
• The dollar increase in Zola revenue year-to-date (first nine months of 2025) was $820,000.
• Zola Q1 2025 revenue showed a 90% year-over-year increase.
• Zola Q2 2025 revenue grew 24% year-over-year.
• Zola Q3 2025 revenues were flat year-over-year.
• The company has maintained gross profit margins exceeding 30% for eleven consecutive quarters as of Q3 2025.
• No price increases were implemented by Arcadia Biosciences, Inc. (RKDA) during 2024 or 2025.
• Total revenue for the first nine months of 2025 was $3.96 million, consisting entirely of Zola coconut water sales.
• Total revenue for Q3 2025 was $1.302 million.

Large national and regional grocery retailers and distributors

These partners are the essential conduit to the health and wellness consumers. Their stocking decisions directly impact Zola's sales volume.

• Zola's year-to-date growth in 2025 was primarily driven by an increase in distribution.
• As of Q1 2025, Zola distribution had grown 70% year-over-year.
• Retail distribution for Zola nearly doubled in 2024.
• The Q3 2024 sales included an incremental $165,000 from the initial sell-in to a large customer, which created a tough comparison for Q3 2025.

Institutional and individual investors focused on turnaround plays

This segment views Arcadia Biosciences, Inc. (RKDA) through the lens of its corporate restructuring and the pending business combination, which is a major factor in investor sentiment.

Financial/Event Metric	Value as of Late 2025 Data
Cash Balance (as of September 30, 2025)	$1.1 million
Credit Loss Recognized on Note Receivable (as of September 30, 2025)	$4.7 million
Q3 2025 Net Income Attributable to Common Stockholders	$856,000
Q3 2025 Earnings Per Share (EPS)	$0.63 per share
Q3 2024 Net Loss Attributable to Common Stockholders	$1.6 million
Q3 2024 Loss Per Share (EPS)	$1.18 per share
Expected Post-Closing Equity Split (Roosevelt Partners / Arcadia Shareholders)	90% / 10%
Analyst Consensus Rating (Last 12 Months)	Sell (1 of 1 analyst rating)
Analyst Revenue Forecast (Average for 2025)	$6.1M
Trailing Twelve Months (TTM) Revenue (as of late 2025)	$5.17 Million USD

The pending business combination with Roosevelt Resources is still in progress, with an amended exchange agreement filed in July 2025.

Strategic partners interested in agricultural biotechnology IP

This segment relates to the monetization and wind-down of legacy agricultural assets, which provided non-recurring revenue and gains in prior periods.

• GLA oil sales, which were present in 2024, were absent in the first nine months of 2025.
• GLA oil sales in the first nine months of 2024 totaled $701,000.
• GLA oil sales in Q3 2024 totaled $217,000.
• Arcadia Biosciences, Inc. (RKDA) sold select patents for $750,000 in March 2025.
• A $2.8 million gain was recognized in 2025 from an agreement with Bioceres Crop Solutions Corp regarding reduced gluten and oxidative stability patents.
• A $4.0 million gain occurred in 2024 from the sale of RS durum wheat patents to Corteva.
• The company eliminated $1 million in contingent liabilities year-to-date Q2 2025 via an agreement with Bioseed Research India.

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Cost Structure

Cost of revenues, primarily for Zola product manufacturing and logistics

For the first nine months of 2025, Cost of revenues increased by $253,000, representing a 12% rise compared to the same period in 2024, mainly due to Zola coconut water costs.

Specifically for Zola, the cost of revenues for the first nine months of 2025 grew by $472,000, which is a 25% increase, directly linked to the 26% growth in Zola sales year-to-date.

Looking at the quarterly progression:

• Cost of revenues for the first quarter of 2025 rose by $211,000, or 45%, entirely from Zola product costs.
• Zola cost of revenues in the first quarter of 2025 increased by $244,000, or 56%.
• In the second quarter of 2025, Cost of revenues increased $191,000, or 30%, consisting only of Zola coconut water costs.
• Zola cost of revenues grew $204,000, or 33%, in the second quarter of 2025.

For context, the total cost of revenues for the full year 2024 was $3 million.

Selling, General, and Administrative (SG&A) expenses, reduced by $1.6 million year-to-date Q3 2025

Arcadia Biosciences, Inc. achieved a significant reduction in overhead. SG&A expenses decreased by $1.6 million for the first nine months of 2025 when compared to the same nine-month period in 2024.

This reduction was $671,000 just in the third quarter of 2025.

The decrease in SG&A for the first quarter of 2025 alone was $324,000, or 16%.

The full-year 2024 SG&A expenses totaled $9.6 million.

Transaction-related costs for the Roosevelt Resources business combination

Costs associated with the strategic transactions appeared in prior periods, influencing the current period's expense comparison. For instance, SG&A expenses for the fourth quarter of 2024 included $700,000 in transaction-related costs.

Total transaction-related costs recorded in the full year 2024, covering the GoodWheat asset sale and the pending Roosevelt Resources transaction, amounted to $2.0 million.

More recently, the CEO noted almost $700,000 in transaction fees during the second quarter of 2025.

Significant non-cash credit loss of $4.7 million on the Above Food note receivable

A major non-cash impact on the cost structure for the first nine months of 2025 was the $4.7 million credit loss recognized related to the note receivable from Above Food.

This loss was heavily weighted in the second quarter of 2025, where a $4.5 million credit loss was established as a reserve for the outstanding principal, accrued interest, and related receivables after the stock election fulfillment.

Employee-related costs for a streamlined corporate team

The year-over-year improvement in SG&A for the first nine months of 2025 was primarily attributed to the absence of certain 2024 expenses.

The reduction was driven by:

• Operating costs present in 2024 but absent in 2025.
• Employee related costs in 2024 that were not incurred in 2025, reflecting the streamlined corporate team.

Here is a snapshot of key financial movements impacting the cost structure for the first nine months of 2025 compared to the first nine months of 2024 (amounts in thousands, unless noted):

Cost Component	Change (9M 2025 vs 9M 2024)	Detail/Context
Cost of Revenues	Increase of $253	Primarily Zola product costs.
Zola Cost of Revenues	Increase of $472 (or 25%)	Driven by 26% increase in Zola sales.
SG&A Expenses	Decrease of $1,600	Reflects streamlined operations and absence of 2024 costs.
Credit Loss (Above Food)	$4,700 recognized	Non-cash credit loss on note receivable for 9M 2025.
Transaction Fees (Q2 2025)	Almost $700	Fees incurred during the second quarter of 2025.

Arcadia Biosciences, Inc. (RKDA) - Canvas Business Model: Revenue Streams

You're looking at how Arcadia Biosciences, Inc. is bringing in money as of late 2025, which is heavily focused on the Zola® brand now that legacy businesses are largely exited. The revenue picture is a mix of product sales and one-time asset monetization events.

The Trailing Twelve Months (TTM) total revenue for Arcadia Biosciences, Inc. stands at approximately $5.17 million USD as of the latest reports. For the third quarter of 2025 alone, revenue was reported at $1.3 million.

The primary driver for product revenue is Zola® coconut water. For the first nine months of 2025, Zola® year-to-date revenues showed strong growth, increasing by 26% year-over-year. This growth helped offset the absence of sales from discontinued product lines, such as GLA oil, which generated $701,000 in the first nine months of 2024.

Monetization of intellectual property (IP) provided significant, non-recurring income. In the first quarter of 2025, Arcadia Biosciences, Inc. completed a sale of select patents for $750,000. Furthermore, for the first nine months of 2025, the company recognized a gain of $2.8 million related to an agreement with Bioceres Crop Solutions Corp to transfer rights for reduced gluten and oxidative stability patents.

Non-operating income from investments also contributed materially to the bottom line. Specifically, in the third quarter of 2025, Arcadia Biosciences, Inc. recognized an unrealized gain of $1.7 million on its holding of Above Food Ingredients Inc. common stock. This stock was received as partial repayment of the note receivable from the prior sale of the GoodWheatTM assets.

The company still retains potential for future revenue from its legacy IP, though specific amounts are not currently realized or guaranteed. This is the area where past licensing and trait sales occurred, such as the $4 million one-time payment from Corteva Agriscience for the Resistant Starch Durum trait in 2024.

Here's a quick look at the key components contributing to the revenue picture:

Revenue Stream Component	Latest Reported Figure/Metric	Period/Context
TTM Total Revenue	$5.17 Million USD	Trailing Twelve Months
Zola® Coconut Water YTD Revenue Growth	26% increase	Year-to-Date Q3 2025
Q1 2025 Patent Sale Proceeds	$750,000	Q1 2025
Q3 2025 Unrealized Gain on Stock	$1.7 million	Q3 2025
2025 IP Transfer Gain (Partial)	$2.8 million gain	First Nine Months of 2025

The current revenue focus is clearly on scaling the Zola® brand, which is the sole product line now generating sales revenue. The IP monetization and stock gains are important for cash flow but are not sustainable, recurring revenue streams in the same way product sales are.

You should track the Q4 2025 results closely to see if the Zola® growth rate holds up against the prior year's large customer sell-in benefit.

• Zola® is the primary product revenue source.
• Legacy IP monetization provided one-time cash events.
• Unrealized gains on equity holdings impact reported income.
• No price increases were implemented during 2024 or 2025.

Finance: draft 13-week cash view by Friday.